COMP <GO>
INDV vs ABBV // 10Y YIELD & FRED MACRO BETA
Indivior Pharmaceuticals Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: INDV 5
— ABBV 8
■ METRIC PARITY
LAST: $35.37 (+0.34%) • MKT CAP: $4.16B
macro-sensitivity
1.15
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
macro-sensitivity
1.15
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (INDV VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | INDV | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 80.20% | 70.20% | +10.00 | INDV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 62.20% | 29.00% | +33.20 | INDV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 13.4x | 33.3x | -19.90 | INDV | /valuation <GO> |
| Free Cash Flow Yield | -2.24% | 3.47% | -5.71 | ABBV | /fcf-yield <GO> |
| Operating Margin | 21.10% | 24.60% | -3.50 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 16.90% | 6.90% | +10.00 | INDV | /net-margins <GO> |
| Revenue Growth (YoY) | 4.30% | 8.60% | -4.30 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.13 | 5.33 | -2.20 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.40% | 7.40% | 0.00 | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 52.2 | 72.8 | -20.54 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 1.15 | 1.15 | 0.00 | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 18.4x | 113.1x | -94.70 | INDV | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.16B | $513.86B | -$509.70B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | INDV REV | ABBV REV | INDV GROSS % | ABBV GROSS % | INDV FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.24B | $61.16B | 80.2% | 70.2% | -$93.0M | $17.82B |
| FY 2024 | $1.19B | $56.33B | 80.6% | 70.0% | $7.0M | $17.83B |
| FY 2023 | $1.09B | $54.32B | 44.0% | 44.0% | -$349.2M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
INDV // BETA 1.15
ABBV // BETA 1.15